
|Videos|April 9, 2013
Episode 24 - Accountable Care Organizations
Advertisement
Episodes in this series

During this segment, David Calabrese, RPh, MHP, and Kenneth L. Schaecher, MD, FACP, CPC, discuss accountable care organizations (ACOs) and their impact on patient care.
Dr Schaecher explains that although ACOs are constructed to benefit healthcare professionals and patients, he fears that an ACO model of care may cause clinicians to under-utilize expensive drug
therapies.
Dr Schaecher hopes that healthcare professionals will continue to make the best choice for their patients and ignore the financial pressures that often play a role in the treatment decision-making process.
Advertisement
Related to this article

In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.

Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.

Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.

The authors found concurrent growth in pharmacy benefit manager market concentration and worsening of patient access measures across states from 2016 to 2025.

AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.

Eosinophil thresholds and documentation rules shape COPD biologic access. At ERS 2026, experts discussed biomarkers, delays, and multidisciplinary care.
Advertisement
Advertisement
Trending on AJMC
1
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
2
FDA Approves Weekly Gefurulimab for Generalized Myasthenia Gravis
3
Nondrug Therapies Ease Cough in Lung Cancer, Pulmonary Rehab Leads Pack
4
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
5

























